Mene Pangalos is the man tasked with nothing less than firing up the discovery engine of Britain’s second-biggest drug maker after its catastrophic fall off the “patent cliff”.
He joined AstraZeneca as head of innovative medicines in 2010, as the company was bracing for patents to expire on a string of its best-selling drugs.
A new $1.7 million lab at the University of Maryland, Baltimore County is designed to teach students about science through experience.
The 3,000-square-foot Science Learning Collaboratory in UMBC’s Meyerhoff Chemistry Building, is a partnership with the Howard Hughes Medical Institute, which paid for the project. UMBC students will take classes in the new lab during the school year and Howard Hughes will use the space during the summer. The university unveiled the new space Monday.
Adventist HealthCare on Monday named Terry Forde its new president and CEO.
The Gaithersburg-based hospital system had already tapped Forde its interim leader following last month’s announcement of CEO Bill Robertson’s planned departure. In February, Robertson said he would leave for a new position with MultiCare Health in Tacoma, Wash. Robertson, 54, had been Adventist’s CEO since April 2000.
FRIDAY, JUNE 13, 2014 8:30 am, Rockville, Maryland
The biomanufacturing industry faces an unprecedented challenge with the emergence of biosimilars. The pathway to approval for biosimilars is a fluid process and several key aspects are still not determined. The University of Maryland and the National Institute of Standards and Technology (NIST) will deliver a one-day symposium on the current trends of characterization and production of biosimilars. On Friday, June 13, 2014 at 8:30 am join the thought-leaders, policy-makers, and creators of biosimilars as we present current trends, ideas, and predictions.
For decades, large companies have gone shopping in Silicon Valley for startups. Lately, the pressure of continuous disruption has forced them to step up the pace.
More often than not, the results of these acquisitions are disappointing.
What can companies learn from others’ failed efforts to integrate startups into large companies? The answer: There are two types of integration strategies, and they depend on where the startup is in its lifecycle.
When Bryan Sivak joined then D.C. mayor Adrian Fenty’s administration as chief technology officer, he was fresh from building his own business. Five years later, Sivak has become something of a government-embedded entrepreneur. He left the District to become Maryland’s first chief innovation officer in 2011. He is now chief technology officer at the Department of Health and Human Services. There, he manages the IDEA Lab, a series of programs that reward innovation, bring private sector leaders into the agency, and provide employees with time and money to pursue ideas. The effort aims to infuse a sense of entrepreneurship in the risk-adverse temperament of government.
Heart disease is the #1 killer of humans — claiming more lives than car accidents, war, famine, and natural disasters.
So it’ll come as good news that scientists at Johns Hopkins have found a drug that acts by stopping any hardening of the arteries, and prevents fat from clogging up blood vessels.
On an industrial park next to Liverpool’s John Lennon airport, drugs companies are involved in research that is driving a new frenzy of multibillion-dollar takeover deals. The focus on this Merseyside site is on creating what could be the next big thing for the sector: biological medicines, derived from living organisms.
In laboratories here and around the world, the quest for the latest blockbuster drug has sparked another flurry of deal activity. Last week saw GlaxoSmithKline of the UK and Swiss rival Novartis agree a multibillion dollar swap of assets, while it emerged that another British firm, AstraZeneca, has been the subject of a £60bn approach from US group Pfizer. And every participant is seeking a deal that will yield a clutch of medical bestsellers.
The EY Entrepreneur Of The Year 2014 finalists have a lot to celebrate. They’ve built their dream companies. Expanded. Innovated. And now EY is recognizing them for their achievements. Help us congratulate these outstanding entrepreneurs. Join us at this years event and see who will take home top honors.
With a pinch of history, a dash of pride, and a heaping helping of collaboration, University of Maryland, Baltimore (UMB) President Jay A. Perman, MD, put forth a winning recipe in his first annual State of the University Address.
Speaking at a packed School of Nursing auditorium on April 24 that included dignitaries such as University System of Maryland (USM) Chancellor William E. Kirwan, PhD, Perman discussed UMB’s recent achievements and the challenges it will confront in the coming year.
